Fmr LLC Purchases 21,462 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Fmr LLC lifted its holdings in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 370.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 27,261 shares of the biopharmaceutical company’s stock after acquiring an additional 21,462 shares during the quarter. Fmr LLC owned approximately 0.11% of Inovio Pharmaceuticals worth $158,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. The Manufacturers Life Insurance Company acquired a new stake in Inovio Pharmaceuticals during the second quarter worth approximately $82,000. Signature Estate & Investment Advisors LLC bought a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at about $88,000. SG Americas Securities LLC bought a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at approximately $71,000. Cornercap Investment Counsel Inc. purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter worth approximately $184,000. Finally, American Century Companies Inc. grew its position in Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 12,100 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $1.84 on Monday. Inovio Pharmaceuticals, Inc. has a one year low of $1.74 and a one year high of $14.75. The stock has a market cap of $48.02 million, a P/E ratio of -0.53 and a beta of 0.75. The stock’s fifty day moving average is $4.53 and its 200 day moving average is $6.82.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Royal Bank of Canada decreased their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. Oppenheimer reduced their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. Finally, HC Wainwright cut their price target on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $38.00.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.